{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:01:20Z","timestamp":1725534080234},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.thromres.2013.05.019","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T05:17:17Z","timestamp":1371532637000},"page":"240-247","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber"],"prefix":"10.1016","volume":"132","author":[{"given":"Michael","family":"Wolzt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazaleh","family":"Gouya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Kapiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Becka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Kubitza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.05.019_bb0005","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1161\/CIR.0b013e318212bb8b","volume":"123","author":"Anderson","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.05.019_bb0010","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.05.019_bb0015","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2013.05.019_bb0020","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1160\/TH10-10-0683","article-title":"Venous and arterial thrombosis \u2013 pathogenesis and the rationale for anticoagulation","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.05.019_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.05.019_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"\"Triple therapy\" rather than \"triple threat\": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2013.05.019_bb0040","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/CIRCULATIONAHA.109.853119","article-title":"New anticoagulants","volume":"121","author":"Eikelboom","year":"2010","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2013.05.019_bb0045","first-page":"P1104","article-title":"Effect of BAY 59\u20137939\u2212a novel, oral, direct Factor Xa inhibitor\u2212on clot-bound Factor Xa activity in vitro","volume":"3","author":"Depasse","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.05.019_bb0050","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59\u20137939\u2212an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2013.05.019_bb0055","article-title":"Rivaroxaban\u2212an oral, direct Factor Xa inhibitor\u2212inhibits tissue factor-mediated platelet aggregation","volume":"5","author":"Perzborn","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.05.019_bb0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.thromres.2013.05.019_bb0065","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.05.019_bb0075","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0080","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.05.019_bb0085","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0090","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0095","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0026-2862(73)90069-1","article-title":"The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi","volume":"5","author":"Baumgartner","year":"1973","journal-title":"Microvasc Res"},{"key":"10.1016\/j.thromres.2013.05.019_bb0110","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.thromres.2011.08.018","article-title":"Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists","volume":"129","author":"Wolzt","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.05.019_bb0115","first-page":"706","article-title":"Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene","volume":"110","author":"Badimon","year":"1987","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0003319710382416","article-title":"Fibrin D-dimer concentration, deep vein thrombosis symptom duration, and venous thrombus volume","volume":"62","author":"Kurklinsky","year":"2011","journal-title":"Angiology"},{"key":"10.1016\/j.thromres.2013.05.019_bb0125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1161\/ATVBAHA.108.182188","article-title":"Biomarkers and venous thromboembolism","volume":"29","author":"Pabinger","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2013.05.019_bb0130","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH07-04-0312","article-title":"Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber","volume":"98","author":"Zafar","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.05.019_bb0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59\u20137939, an oral, direct Factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.05.019_bb0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2008.07.015","article-title":"Determination of rivaroxaban \u2013 a novel, oral, direct Factor Xa inhibitor \u2013 in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"872","author":"Rohde","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.thromres.2013.05.019_bb0145","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1538-7836.2007.02429.x","article-title":"In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct Factor Xa inhibitor rivaroxaban","volume":"5","author":"Gerotziafas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.05.019_bb0150","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59\u20137939 \u2013 an oral, direct Factor Xa inhibitor \u2013 after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2013.05.019_bb0155","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor \u2013 are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2013.05.019_bb0160","article-title":"Combining rivaroxaban with acetylsalicylic acid increases antithrombotic potency without affecting bleeding times in animal models","volume":"5","author":"Perzborn","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2013.05.019_bb0165","first-page":"189","article-title":"Rivaroxaban, a novel, oral, direct Factor Xa inhibitor, enhanced the effects of clopidogrel and acetylsalicylic acid in rats","volume":"28","author":"Perzborn","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.05.019_bb0170","article-title":"Concomitant administration of antiplatelet agents enhances the antithrombotic effects of rivaroxaban in vitro and in vivo","volume":"304","author":"Perzborn","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.05.019_bb0175","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1055\/s-0037-1613294","article-title":"Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin","volume":"88","author":"Shimbo","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.05.019_bb0180","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1365-2141.1996.d01-1892.x","article-title":"Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood","volume":"95","author":"Orvim","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2013.05.019_bb0185","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"Gibson","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2013.05.019_bb0190","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.05.019_bb0195","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813002119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813002119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T19:11:00Z","timestamp":1563217860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813002119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0049384813002119"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.05.019","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}